Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Selexis and OSE expand business relationship
July 2017
SHARING OPTIONS:

GENEVA & NANTES, France—Selexis SA and OSE Immunotherapeutics SA have inked a commercial license agreement granting OSE access to high-performance research cell banks (RCBs) from the Selexis SUREtechnology Platform. This agreement is built on a previous deal announced by the companies in November 2016 and will support the clinical development of OSE’s interleukin receptor 7 antagonist, OSE-127, which is being developed as a potential treatment for inflammatory bowel diseases.
 
“The broad applicability of our technology, coupled with our robust cell lines, provides our partners with the opportunity to continue working with us long-term across their drug development cycles. We look forward to helping OSE Immunotherapeutics realize the full potential of OSE-127,” said Dr. Marco Bocci, Selexis’ vice president of licensing and business development. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.